Tularemia: What to Do When First-Line Antimicrobial Therapy Fails to Resolve Fever
Clinical Scenario
This protocol addresses tularemia cases in which initial antimicrobial treatment has not produced the expected clinical response. It defines the next step when first-line therapy falls short of the key early benchmark and an alternative antimicrobial approach becomes necessary.
Previous Treatment & Failure Condition
First-line antimicrobial monotherapy — ciprofloxacin, levofloxacin, gentamicin, or doxycycline — is expected to achieve defervescence (resolution of fever), typically within about 4 days of treatment initiation. Failure to reach this target is the trigger for escalation to the alternative regimen described by this protocol.
Treatment Approach (Partial Overview)
When first-line agents cannot be continued or have not achieved the expected response, this protocol specifies alternative antimicrobial monotherapy drawn from distinct drug classes not used in the first line — including a tetracycline option and alternative agents within the fluoroquinolone and aminoglycoside classes. Agent selection criteria, specific choices within each class, and all dosing parameters are contained in the complete protocol.
References
- Although doxycycline has replaced tetracycline as first-line treatment of tularemia in adults, tetracycline remains an acceptable second-line agent.
- For example, moxifloxacin and ofloxacin are listed as alternative fluoroquinolone options and amikacin, tobramycin, and plazomicin are included as alternative aminoglycoside options.
- Other aminoglycosides, namely amikacin, tobramycin, and plazomicin, can be considered as alternative treatment options if gentamicin is contraindicated and first-line antimicrobial drugs are not available.
View source ↗